The effect of thymopoietin(32-36) and ubiquitin on spontaneous immunopathology of New Zealand mice

M. Eric Gershwin, W. Kruse, G. Golstein

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

The effects of synthetic thymopoeitin32-36 and purified ubiquitin, in daily doses of 1 or 10 μg, were studied in New Zealand mice. The most striking result was a 4-month delay in the appearance of Coombs' positive tests or Coombs' antibodies in New Zealand black (NZB) mice treated from 4 wk of age with ubiquitin. Ubiquitin also reduced the spleen weight in the animals and stimulated suppressor T cell activity in shorter term studies of older NZB and black and white (B/W) mice. Thymopoietin was also active in this assay and improved the mitogen responsiveness of lymph node cells in older treated NZB and B/W mice. Thymopoietin injections, from 4 wk of age, reduced the titer of Coombs' antibodies and thymocytotoxic antibodies in NZB mice and caused an increase in Thy 1+ spleen cells in these animals. In correspondingly treated B/W mice, thymopoietin reduced the anti-DNA antibody titer. While our present injection protocol did not result in clinical cure of the genetically determined autoimmune diseases of NZB and B/W mice, they do point to the feasibility of selective immunoregulation by these peptides in diseases associated with altered states of immune reactivity.

Original languageEnglish (US)
Pages (from-to)610-620
Number of pages11
JournalJournal of Rheumatology
Volume6
Issue number6
StatePublished - 1979

Fingerprint

Thymopoietins
Ubiquitin
New Zealand
Antibodies
Spleen
Coombs Test
Injections
Antinuclear Antibodies
Mitogens
Autoimmune Diseases
Lymph Nodes
T-Lymphocytes
Weights and Measures
Peptides
hydroquinone

ASJC Scopus subject areas

  • Immunology
  • Rheumatology

Cite this

The effect of thymopoietin(32-36) and ubiquitin on spontaneous immunopathology of New Zealand mice. / Gershwin, M. Eric; Kruse, W.; Golstein, G.

In: Journal of Rheumatology, Vol. 6, No. 6, 1979, p. 610-620.

Research output: Contribution to journalArticle

@article{5cccee5ef874476aa9cdffde39fb7d15,
title = "The effect of thymopoietin(32-36) and ubiquitin on spontaneous immunopathology of New Zealand mice",
abstract = "The effects of synthetic thymopoeitin32-36 and purified ubiquitin, in daily doses of 1 or 10 μg, were studied in New Zealand mice. The most striking result was a 4-month delay in the appearance of Coombs' positive tests or Coombs' antibodies in New Zealand black (NZB) mice treated from 4 wk of age with ubiquitin. Ubiquitin also reduced the spleen weight in the animals and stimulated suppressor T cell activity in shorter term studies of older NZB and black and white (B/W) mice. Thymopoietin was also active in this assay and improved the mitogen responsiveness of lymph node cells in older treated NZB and B/W mice. Thymopoietin injections, from 4 wk of age, reduced the titer of Coombs' antibodies and thymocytotoxic antibodies in NZB mice and caused an increase in Thy 1+ spleen cells in these animals. In correspondingly treated B/W mice, thymopoietin reduced the anti-DNA antibody titer. While our present injection protocol did not result in clinical cure of the genetically determined autoimmune diseases of NZB and B/W mice, they do point to the feasibility of selective immunoregulation by these peptides in diseases associated with altered states of immune reactivity.",
author = "Gershwin, {M. Eric} and W. Kruse and G. Golstein",
year = "1979",
language = "English (US)",
volume = "6",
pages = "610--620",
journal = "Journal of Rheumatology",
issn = "0315-162X",
publisher = "Journal of Rheumatology",
number = "6",

}

TY - JOUR

T1 - The effect of thymopoietin(32-36) and ubiquitin on spontaneous immunopathology of New Zealand mice

AU - Gershwin, M. Eric

AU - Kruse, W.

AU - Golstein, G.

PY - 1979

Y1 - 1979

N2 - The effects of synthetic thymopoeitin32-36 and purified ubiquitin, in daily doses of 1 or 10 μg, were studied in New Zealand mice. The most striking result was a 4-month delay in the appearance of Coombs' positive tests or Coombs' antibodies in New Zealand black (NZB) mice treated from 4 wk of age with ubiquitin. Ubiquitin also reduced the spleen weight in the animals and stimulated suppressor T cell activity in shorter term studies of older NZB and black and white (B/W) mice. Thymopoietin was also active in this assay and improved the mitogen responsiveness of lymph node cells in older treated NZB and B/W mice. Thymopoietin injections, from 4 wk of age, reduced the titer of Coombs' antibodies and thymocytotoxic antibodies in NZB mice and caused an increase in Thy 1+ spleen cells in these animals. In correspondingly treated B/W mice, thymopoietin reduced the anti-DNA antibody titer. While our present injection protocol did not result in clinical cure of the genetically determined autoimmune diseases of NZB and B/W mice, they do point to the feasibility of selective immunoregulation by these peptides in diseases associated with altered states of immune reactivity.

AB - The effects of synthetic thymopoeitin32-36 and purified ubiquitin, in daily doses of 1 or 10 μg, were studied in New Zealand mice. The most striking result was a 4-month delay in the appearance of Coombs' positive tests or Coombs' antibodies in New Zealand black (NZB) mice treated from 4 wk of age with ubiquitin. Ubiquitin also reduced the spleen weight in the animals and stimulated suppressor T cell activity in shorter term studies of older NZB and black and white (B/W) mice. Thymopoietin was also active in this assay and improved the mitogen responsiveness of lymph node cells in older treated NZB and B/W mice. Thymopoietin injections, from 4 wk of age, reduced the titer of Coombs' antibodies and thymocytotoxic antibodies in NZB mice and caused an increase in Thy 1+ spleen cells in these animals. In correspondingly treated B/W mice, thymopoietin reduced the anti-DNA antibody titer. While our present injection protocol did not result in clinical cure of the genetically determined autoimmune diseases of NZB and B/W mice, they do point to the feasibility of selective immunoregulation by these peptides in diseases associated with altered states of immune reactivity.

UR - http://www.scopus.com/inward/record.url?scp=0018651935&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018651935&partnerID=8YFLogxK

M3 - Article

VL - 6

SP - 610

EP - 620

JO - Journal of Rheumatology

JF - Journal of Rheumatology

SN - 0315-162X

IS - 6

ER -